Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Stryker (SYK)

Stryker elects James E. Davis, Quest Diagnostics CEO, to board effective January 1, 2027

Neutral Impact 3 of 5 leadership

Stryker's board increased its size from 11 to 12 directors and elected James E. Davis, CEO and President of Quest Diagnostics, to fill the new seat. The election takes effect January 1, 2027, and Davis has not yet been assigned to any board committee.

Key points

  • Board expanded from 11 to 12 authorized directors on November 3, 2026
  • James E. Davis, CEO and President of Quest Diagnostics since November 2022, elected to fill the vacancy effective January 1, 2027
  • Davis will receive non-employee director compensation consistent with other directors and will sign the company's standard director indemnification agreement
  • No financial results or guidance were included in the filing

The filing

CompanyStryker (SYK)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:16 PM ET
Accession number0001193125-26-453635

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 4:22 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.